Trexquant Investment LP Increases Stock Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Trexquant Investment LP raised its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 85.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 343,883 shares of the company's stock after purchasing an additional 158,520 shares during the period. Trexquant Investment LP owned approximately 0.07% of Elanco Animal Health worth $4,164,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Wilmington Savings Fund Society FSB bought a new position in shares of Elanco Animal Health during the 3rd quarter valued at $35,000. Jones Financial Companies Lllp increased its stake in Elanco Animal Health by 95.6% in the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock worth $51,000 after purchasing an additional 2,059 shares during the period. SRS Capital Advisors Inc. lifted its position in Elanco Animal Health by 221.2% in the fourth quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company's stock valued at $60,000 after purchasing an additional 3,411 shares during the last quarter. MRP Capital Investments LLC bought a new position in shares of Elanco Animal Health in the fourth quarter worth approximately $61,000. Finally, Blue Trust Inc. lifted its holdings in Elanco Animal Health by 47.7% in the 4th quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock worth $71,000 after buying an additional 1,894 shares during the period. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Trading Down 11.8 %

ELAN stock traded down $1.11 during mid-day trading on Thursday, reaching $8.27. The company had a trading volume of 2,145,830 shares, compared to its average volume of 4,877,606. The firm has a 50 day moving average of $10.71 and a 200 day moving average of $12.10. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. Elanco Animal Health Incorporated has a 12 month low of $8.03 and a 12 month high of $18.80. The company has a market capitalization of $4.11 billion, a PE ratio of 20.74, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company's revenue for the quarter was down 1.4% on a year-over-year basis. During the same period last year, the firm earned $0.08 earnings per share. On average, equities analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Barclays decreased their price target on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Morgan Stanley reduced their price objective on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 26th. Stifel Nicolaus decreased their price objective on shares of Elanco Animal Health from $18.00 to $16.00 and set a "buy" rating for the company in a report on Friday, February 21st. UBS Group reduced their price target on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a research note on Wednesday, February 26th. Finally, Piper Sandler cut their price target on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a research note on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $15.17.

Insider Activity

In other news, Director Lawrence Erik Kurzius bought 10,000 shares of Elanco Animal Health stock in a transaction on Tuesday, March 11th. The stock was acquired at an average cost of $10.20 per share, for a total transaction of $102,000.00. Following the completion of the acquisition, the director now owns 111,459 shares of the company's stock, valued at $1,136,881.80. This trade represents a 9.86 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.57% of the company's stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.